- Home
- SHMD vs QNCX Comparison
SHMD vs QNCX Comparison
Compare SHMD & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHMD
- QNCX
- Stock Information
- Founded
- SHMD 1864
- QNCX 2012
- Country
- SHMD Germany
- QNCX United States
- Employees
- SHMD N/A
- QNCX N/A
- Industry
- SHMD
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SHMD
- QNCX Health Care
- Exchange
- SHMD Nasdaq
- QNCX Nasdaq
- Market Cap
- SHMD 123.6M
- QNCX 47.7M
- IPO Year
- SHMD N/A
- QNCX 2019
- Fundamental
- Price
- SHMD N/A
- QNCX $1.64
- Analyst Decision
- SHMD
- QNCX Strong Buy
- Analyst Count
- SHMD 0
- QNCX 5
- Target Price
- SHMD N/A
- QNCX $8.00
- AVG Volume (30 Days)
- SHMD 16.7K
- QNCX 353.3K
- Earning Date
- SHMD 02-25-2025
- QNCX 08-12-2025
- Dividend Yield
- SHMD N/A
- QNCX N/A
- EPS Growth
- SHMD N/A
- QNCX N/A
- EPS
- SHMD N/A
- QNCX N/A
- Revenue
- SHMD $85,165,542.00
- QNCX N/A
- Revenue This Year
- SHMD N/A
- QNCX N/A
- Revenue Next Year
- SHMD N/A
- QNCX N/A
- P/E Ratio
- SHMD N/A
- QNCX N/A
- Revenue Growth
- SHMD N/A
- QNCX N/A
- 52 Week Low
- SHMD $1.86
- QNCX $0.51
- 52 Week High
- SHMD $5.17
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- SHMD N/A
- QNCX 64.95
- Support Level
- SHMD N/A
- QNCX $1.48
- Resistance Level
- SHMD N/A
- QNCX $1.68
- Average True Range (ATR)
- SHMD 0.00
- QNCX 0.14
- MACD
- SHMD 0.00
- QNCX 0.02
- Stochastic Oscillator
- SHMD 0.00
- QNCX 85.71
About SHMD SCHMID Group N.V. Class A Ordinary Shares
Schmid Group NV is a global supplier of equipment, software and services for various industries such as printed circuit board (PCB), substrate manufacturing, photovoltaics, and glass and energy storage with a focus on the highest end of this market in terms of technology and performance. It focuses on a modular product portfolio of machinery to use in the manufacturing of high-end PCB equipment and semiconductor packaging devices which includes common flexible circuit fabrication techniques such as subtractive, semi-additive processes (SAP) and modified semi-additive processes (mSAP).
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.